SEQSTER Announces Expanded Partnership with Praxis Precision Medicines to Accelerate Clinical Trials in CNS Disorders

Core Insights - SEQSTER and Praxis Precision Medicines have expanded their partnership to enhance clinical trials, data collection, and real-world evidence generation for Praxis's clinical development programs [1][2][4] Group 1: Partnership and Collaboration - SEQSTER has been integral to Praxis's clinical trial execution, improving trial enrollment efficiency and capturing necessary longitudinal real-world data [2][3] - The partnership focuses on advancing the ENERGY program, which includes the EMPOWER observational study and POWER clinical studies, attracting over 5,000 patients with epilepsy [3][4] Group 2: Company Profiles - Praxis Precision Medicines is a leading biopharmaceutical company specializing in central nervous system (CNS) disorders, utilizing genetic insights to develop therapies for various neurological conditions [5] - SEQSTER is a healthcare technology company that consolidates patient-consented health data into a unified view, supporting research and patient health management with a repository of 150 million patients [6][7]